In medical terms, Primary Periodic Paralysis is referred to as a group of rare channelopathies manifesting as recurrent attacks of muscle weakness or temporary paralysis often precipitated by triggers.3
Primary Periodic Paralysis is very rare, affecting about 4,000 to 5,000 diagnosed individuals in the United States.4 Although there are related variants, the most common forms are hyperkalemic and hypokalemic PPP.5-9
PPP often has nonspecific and episodic symptoms that mimic those of more common diseases, resulting in years of diagnostic delays and misdiagnoses1
Average time from onset of symptoms to correct diagnosis is 26 years†2
|Typically precipitated by triggers, which vary from patient to patient (ie, foods rich in potassium or carbohydrates, rest after exercise, exposure to cold, and stress)1,10,11|
|Acute attacks of flaccid paralysis may be focal or generalized; episodes vary in duration, severity, and frequency1,10|
|Patients have reported experiencing lingering symptoms after an attack, including weakness, extreme fatigue, muscle pain, and clumsiness1|
|As they age, some patients may experience permanent muscle weakness, further impacting their quality of life over time2|
†Based on a survey of 66 self-selected patients over the age of 40 years with a clinical diagnosis of Primary Periodic Paralysis who sought support via the Internet.2
Strongbridge Biopharma sponsored an educational segment about Primary Periodic Paralysis on The Balancing Act, “Behind the Mystery: Rare and Genetic Diseases.” The segment features Linda Feld, Vice President of Periodic Paralysis Association (PPA), and Steve Cannon, MD, PhD, neurologist and professor of physiology at UCLA. A broad range of topics related to Primary Periodic Paralysis are addressed within the segment, including symptoms, triggers, misdiagnosis, and genetic testing.
Uncovering Periodic Paralysis is a no-cost genetic testing program for those who have episodic muscle weakness or temporary paralysis provoked by common triggers for hyperkalemic or hypokalemic periodic paralysis. To learn more, please visit www.uncoveringperiodicparalysis.com. You can also download the patient brochure or HCP brochure.
What is KEVEYIS?
KEVEYIS (pronounced keh-VAY-iss) (dichlorphenamide) is a prescription drug used to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and other similar diseases.
What should you tell your healthcare provider before taking KEVEYIS?
Tell your doctor if you are allergic to dichlorphenamide or other sulfa drugs; if you take high doses of aspirin, or if you have lung or liver disease; if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed.
What should you know about KEVEYIS?
What are the most common side effects with KEVEYIS?
The most common side effects are a feeling of numbness, tingling or burning (“pins and needles”) in the toes, feet, hands or fingers; trouble with memory or thinking; feeling confused; and unpleasant taste in the mouth.
These are not all of the possible side effects of KEVEYIS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For accessibility-related questions, comments, or concerns about this digital property, please email [email protected] and we will reply to your message.
© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V20 10/2020